The purpose of this study is to compare the incidence of hospitalization for acute kidney injury among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of other oral antidiabetic drugs in classes other than Dipeptidyl peptidase IV (DPP4) inhibitors.
Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice. This will be a prospectively-designed database cohort study comparing hospitalizations for acute kidney injury among new initiators of Saxagliptin compared to those who are new initiators of OADs in classes other than DPP4 inhibitors. The study time frame will be from 2009 through 2014.
Study Type
OBSERVATIONAL
Enrollment
113,505
Hospital admission for acute kidney injury
Time frame: 52 months
Deaths due to acute kidney injury
Time frame: 18 months
Deaths due to acute kidney injury
Time frame: 36 months
Deaths due to acute kidney injury
Time frame: 54 months
Hospitalizations for acute kidney injury and/or death due to acute kidney injury
Time frame: 18 months
Hospitalizations for acute kidney injury and/or death due to acute kidney injury
Time frame: 36 months
Hospitalizations for acute kidney injury and/or death due to acute kidney injury
Time frame: 54 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.